Perioperative blood loss of penitents with abdominal surgery (only medical procedures for the treatment of diseases of abdominal organs such as stomach, intestines, liver, gallbladder, pancreas, spleen, kidney, bladder, etc., including open surgery and laparoscopic surgery)
Conditions
Interventions
Cohort 1: hemocoagulase bothrops atrox for injection:None
Cohort 2: haemocoagulase agkistrodon for injection:None
Cohort 3: thrombin powder:None
Cohort 4: tranexamic acid injection:None
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.>=18 years of age, gender is not limited; 2.Patients with abdominal surgery (only medical procedures for the treatment of abdominal organs such as stomach, intestines, liver, gallbladder, pancreas, spleen, kidney, bladder, etc., including open surgery and laparoscopic surgery) using one of the following hemostatic drugs perioperatively, including but not limited to haemocoagulase agkistrodon for injection, hemocoagulase bothrops atrox for injection, thrombin powder or tranexamic acid injection; 3.Normal coagulation function: international normalized ratio (INR) <=1.5 or activated partial thromboplastin time (APTT) <=1.5× ULN;
Exclusion criteria
Exclusion criteria: 1.Patients with hematologic disorders, including coagulation disorders or bleeding tendency; 2.Patients with severe cardiovascular and cerebrovascular diseases within 6 months before enrollment, including transient ischemic attack, nondisabling ischemic stroke, myocardial infarction, unstable angina, intracranial hemorrhage, etc. 3.Patients with the usage of drugs that affect the function of the coagulation system within 1 week before surgery (including but not limited to 6-aminocaproic acid, trantolunic acid, carbazochrome sodium sulfonate, terlipressin, etamsylate, yunnan baiyao, etc.); 4.Patients who paticipated within 1 month before enrollment or is planning to participate in interventional clinical trials related to hemostatic drugs that affect coagulation function. 5.Patients who are not suitable for enrollment assessed by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence, severity, and duration of adverse events and complications (deep vein thrombosis, pulmonary embolism, infection, rebleeding, etc.) during hospitalization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative blood transfusion;Economics;Changes in levels of coagulation parameters before and after surgery;Estimated total blood loss;Changes in hematologic and biochemical parameters after surgery;Medical resource utilization;Changes in levels of coagulation parameters before and after surgery; | — |
Countries
China
Contacts
Public ContactLi Jing
The Affiliated Hospital of Qingdao University
Outcome results
None listed